Drug Profile


Alternative Names: LptD; PEM antibiotic (POL7080) - Polyphor; POL 7080; RG 7929

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor
  • Class Antibacterials; Cyclic peptides
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pseudomonal infections
  • Phase I Gram-negative infections

Most Recent Events

  • 26 Sep 2016 Chemical structure information added
  • 26 Jul 2016 Pharmacokinetics data from a phase II trial in Pseudomonas aeruginosa infections presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (CMID-2016)
  • 16 Jun 2016 Polyphor terminates a phase II trial for Pseudomonal infections in Spain and Greece (NCT02096328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top